TNF Receptor Inhibitor

By Targets:	TNF Receptor (12) Adenosine Receptor (1) Apoptosis (2) Autophagy (2) Bacterial (1) Calcium Channel (1) CaSR (1) Complement System (1) COX (2) Dopamine Receptor (1) Endogenous Metabolite (1) GLUT (1) Histamine Receptor (2) Interleukin Related (4) NF-κB (2) NO Synthase (1) NOD-like Receptor (NLR) (1) PGE synthase (1) Prostaglandin Receptor (1) Reactive Oxygen Species (1) RIP kinase (1) Toll-like Receptor (TLR) (4) Wnt (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (2) Endocrinology (1) Inflammation/Immunology (19) Metabolic Disease (1) Neurological Disease (2)
Click Chemistry:	Alkynes (1)

Targets Recommended: TNF Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0297

Sinensetin 5 Publications Verification Pedalitin permethyl ether	PGE synthase TNF Receptor	Others
Sinensetin is a methylated flavonoid found in fruits that has strong anti-vascular and anti-inflammatory properties.

HY-111255

SPD304 4 Publications Verification	TNF Receptor	Cancer
SPD304 is a selective *TNF-α* inhibitor, which promotes dissociation of TNF trimers and therefore blocks the interaction of TNF and its receptor. SPD304 has an IC₅₀ of 22 µM for inhibiting in vitro TNF receptor 1 (TNFR1) binding to TNF-α .

HY-111255A

SPD304 dihydrochloride 4 Publications Verification	TNF Receptor	Inflammation/Immunology
SPD304 dihydrochloride is a selective *TNF-α* inhibitor, which promotes dissociation of TNF trimers and therefore blocks the interaction of TNF and its receptor. SPD304 has an IC₅₀ of 22 µM for inhibiting in vitro TNF receptor 1 (TNFR1) binding to TNF-α .

HY-108847

Etanercept 4 Publications Verification	TNF Receptor Bacterial	Inflammation/Immunology Cancer
Etanercept, a dimeric fusion protein that binds TNF, acts as a *TNF* inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .

HY-P2612

WP9QY	TNF Receptor	Others
WP9QY, TNF-a Antagonist, TNF-a Antagonist is a biological active peptide. (This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I. It prevents interactions of TNF with its receptor. This TNF antagonist is a useful template for the development of small molecular inhibitors to prevent both inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.)

HY-122786

3-O-Methylviridicatin	TNF Receptor	Inflammation/Immunology
3-O-Methylviridicatin is an inhibitor of TNF-α.3-O-Methylviridicatin inhibits TNF-a synthesis instead of the activity. 3-O-Methylviridicatin can be used in study anti-in?ammatory agents .

HY-123984

LTβR-IN-1	NF-κB	Metabolic Disease
LTβR-IN-1 is a potent, selective *lymphotoxin β receptor* (LTβR)** inhibitor. LTβR-IN-1 also selectively inhibits the nuclear translocation of p52 depended on TNF12A, instead of the nuclear translocation of p65 mediated by TNF-α receptor. LTβR-IN-1 regulates the NF-kB signaling pathway IN a ligand-independent manner .

HY-108162A

Ataquimast	COX	Inflammation/Immunology
Ataquimast is a COX-2 inhibitor that inhibits the release of leukotrienes, TNF-α and GM-CSF. Ataquimast can be used in the study of advanced receptor-positive breast cancer .

HY-108162

Ataquimast free base	COX	Inflammation/Immunology
Ataquimast free base is a COX-2 inhibitor that inhibits the release of leukotrienes, TNF-α and GM-CSF. Ataquimast free base can be used in the study of advanced receptor-positive breast cancer .

HY-N11768

4-Methoxylonchocarpin	NF-κB Interleukin Related Toll-like Receptor (TLR)	Inflammation/Immunology
4-Methoxylonchocarpin is an orally active anti-inflammatory agent. 4-methoxylonchocarpin inhibits the binding of LPS to *Toll-like Receptor* (TLR) TLR4** to inhibit NF-κB activation and TNF Receptor and IL-6 expression. 4-Methoxylonchocarpin also inhibits the phosphorylation of TGF-beta activated kinase 1 and TNBS-induced expression of IL-1β, IL-17A, and TNF. 4-methoxylonchocarpin can improve 2,4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis mouse model .

HY-P0224

N-Formyl-Met-Leu-Phe 5+ Cited Publications fMLP; N-Formyl-MLF	TNF Receptor	Inflammation/Immunology
N-Formyl-Met-Leu-Phe (fMLP; N-Formyl-MLF) is a chemotactic peptide and a specific ligand of N-formyl peptide receptor (FPR). N-Formyl-Met-Leu-Ph is reported to inhibit *TNF-alpha* secretion.

HY-128686

KAG-308 1 Publications Verification	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
KAG-308 is a potent selective and orally active agonist of EP4 receptor (a prostaglandin E2 receptor subtype), suppresses colitis and promotes histological mucosal healing, potently inhibits TNF-α production. KAG-308 shows a K_i and an EC₅₀ of 2.57 nM and 17 nM for human EP4 receptor, respectively, more selective over EP1, EP2, EP3 and IP receptor .

HY-W014049

N'-Nitro-D-arginine	NO Synthase	Others
N'-Nitro-D-arginine, a nitric oxide synthesis inhibitor, also is a vasodilator that relaxes the smooth muscles and increases blood flow to the penis, improving erections. N'-Nitro-D-arginine also inhibits neutrophil migration by blocking receptors for tumour necrosis factor alpha (TNFα) and interleukin 8 (IL8) .

HY-B0164

Mizolastine	Histamine Receptor	Inflammation/Immunology
Mizolastine is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine effectively inhibits mRNA expression of VEGF165, VEGF120, *TNF-α* and KC. Mizolastine can be used in studies of allergic rhinitis and chronic idiopathic urticarial .

HY-B0164A

Mizolastine dihydrochloride	Histamine Receptor	Inflammation/Immunology
Mizolastine dihydrochloride is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine dihydrochloride effectively inhibits mRNA expression of VEGF165, VEGF120, *TNF-α* and KC. Mizolastine dihydrochloride can be used in studies of allergic rhinitis and chronic idiopathic urticarial .

HY-128348

PK68	RIP kinase	Inflammation/Immunology Cancer
PK68 is a potent orally active and specifical type II inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC₅₀ of ~90 nM, displays inhibition of RIPK1-dependent necroptosis. PK68 powerfully ameliorates TNF-induced systemic inflammatory response syndrome, and can be used for the research of inflammatory disorders and cancer metastasis .

HY-11109

Resatorvid Maximum Cited Publications 354 Publications Verification TAK-242; CLI-095	Toll-like Receptor (TLR) TNF Receptor Interleukin Related Autophagy	Inflammation/Immunology Cancer
Resatorvid (TAK-242) is a selective *Toll-like receptor* 4 (TLR4)** inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC_50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases .

HY-148141

JPE-1375	Complement System	Inflammation/Immunology
JPE-1375 is a *complement C5a receptor* 1 (C5aR1*) antagonist. JPE-1375 effectively inhibits* polymorphonuclear leukocyte mobilization (EC₅₀=6.9 µM) and reduces *TNF* levels (EC₅₀=4.5 µM) in mice. JPE-1375 can be used in studies of autoimmune and inflammatory diseases .

HY-12557

γ-Glutamylvaline	CaSR Wnt TNF Receptor	Inflammation/Immunology
γ-Glutamylvaline is an activator of CaSR with anti-inflammatory activity. γ-Glutamylvaline inhibits *TNF-α*-induced proinflammatory cytokine production and increases Wnt5a expression. γ-Glutamylvaline activates calcium-sensing receptor pathways in adipocytes of 3T3-L1 mice and prevents low-grade chronic inflammation .

HY-128598

MD2-TLR4-IN-1	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
MD2-TLR4-IN-1 (compound 22m) is an inhibitor of myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex, inhibiting lipopolysaccharides (LPS)-induced expression of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) in macrophages with IC₅₀ values of 0.89 μM and 0.53 μM, respectively .

HY-101849

Fasentin 4 Publications Verification	GLUT TNF Receptor Apoptosis	Cardiovascular Disease Cancer
Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC₅₀=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity .

HY-124151

Adenosine-2'-monophosphate 2'-AMP; Adenosine 2'-phosphate; AMP 2'-phosphate	Adenosine Receptor Endogenous Metabolite	Neurological Disease
Adenosine-2'-monophosphate (2'-AMP) is converted by extracellular 2’,3'-CAMP. Adenosine-2'-monophosphate is further metabolized to extracellular adenosine (a mechanism called the extracellular 2’,3’-cAMP-adenosine pathway). Adenosine-2'-monophosphate inhibits LPS-induced TNF-α and CXCL10 production via A_2A receptor activation .

HY-P99361

Enavatuzumab PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)	TNF Receptor	Cancer
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .

HY-B1077

Penfluridol 5 Publications Verification R-16341	Calcium Channel Dopamine Receptor Autophagy Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Penfluridol (R-16341) is a potent, long-acting, first-generation, oral diphenylbutylpiperidine antipsychotic agent by targeting D2-like dopamine receptor. Penfluridol effectively inhibits TNFα-induced NF-κB activation and alleviates the severity of arthritis and colitis in vivo. Penfluridol is a Ca ²⁺-calmodulin inhibitor. Penfluridol induces apoptosis and autophagy. Penfluridol is used for chronic schizophrenia, acute psychosis, Tourette syndrome and autoimmune diseases. Penfluridol inhibites the growth of E. faecalis planktonic cells with the MIC of 7.81 µg/ml .

HY-130252

YQ128 1 Publications Verification	NOD-like Receptor (NLR) Interleukin Related	Inflammation/Immunology
YQ128 is a potent and selective second-generation *NLRP3 (NOD-like receptor* P3) inflammasome** inhibitor with an IC₅₀ of 0.30 μM. YQ128 significantly and selectively suppresses the production of IL-1β, but not TNF-α, and it can cross the BBB to reach the CNS. YQ128 has anti-inflammatory activity . YQ128 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-19744

T6167923 10+ Cited Publications
T6167923 is a selective inhibitor of MyD88-dependent signaling pathways. T6167923 directly binds to Toll/IL1 receptor (TIR) domain of MyD88 and disrupts MyD88 homodimeric formation. T6167923 inhibits NF-κB driven Staphylococcus enterotoxin AP (SEAP) activity, and improves anti-inflammatory activity with IC₅₀s of 2.7 μM, 2.9 μM, 2.66 μM and 2.66 μM for IFN-γ, IL-1β, IL-6 and TNF-α, respectively .

HY-124750

NecroX-7	TNF Receptor Interleukin Related Toll-like Receptor (TLR) Reactive Oxygen Species	Cardiovascular Disease Inflammation/Immunology
NecroX-7 is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. NecroX-7 inhibits the HMGB1-induced release of *TNF* and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 can be used graft-versus-host disease (GVHD) research .

Cat. No.	Product Name

HY-L161

Cytokine Inhibitors Library	820 Compounds compounds
Cytokines are a kind of low molecular soluble proteins synthesized and secreted by immunogen, mitogen or other factors. They have functions of regulating innate and adaptive immune responses, promoting hematopoiesis, stimulating cell activation, proliferation and differentiation. The process of releasing a large number of cytokines is also called “Cytokine storm”, which can cause damage to many tissues and organs in the body. Cytokine is involved in the pathogenesis of many human diseases, including cancer, diabetes, chronic inflammatory diseases and so on. Cytokine inhibitors are a class of essential compounds that act by directly inhibiting the synthesis and release of cytokine or blocking the binding of cytokine to their receptors. Cytokine inhibitors are important compounds for the study of tumor and autoimmune diseases. MCE designs a unique collection of 820 cytokine inhibitors, mainly targeting the receptor interleukin (IL), colony-stimulating factor (CSF), interferon (IFN), tumor necrosis factor (TNF), growth factor (GF) and chemokine, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases and anti-autoimmune diseases compounds.

Cytokine Inhibitors Library

820 Compounds compounds

Cytokines are a kind of low molecular soluble proteins synthesized and secreted by immunogen, mitogen or other factors. They have functions of regulating innate and adaptive immune responses, promoting hematopoiesis, stimulating cell activation, proliferation and differentiation. The process of releasing a large number of cytokines is also called “Cytokine storm”, which can cause damage to many tissues and organs in the body. Cytokine is involved in the pathogenesis of many human diseases, including cancer, diabetes, chronic inflammatory diseases and so on. Cytokine inhibitors are a class of essential compounds that act by directly inhibiting the synthesis and release of cytokine or blocking the binding of cytokine to their receptors. Cytokine inhibitors are important compounds for the study of tumor and autoimmune diseases.

MCE designs a unique collection of 820 cytokine inhibitors, mainly targeting the receptor interleukin (IL), colony-stimulating factor (CSF), interferon (IFN), tumor necrosis factor (TNF), growth factor (GF) and chemokine, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases and anti-autoimmune diseases compounds.

Cat. No.	Product Name	Target	Research Area

HY-P0224

N-Formyl-Met-Leu-Phe 5+ Cited Publications fMLP; N-Formyl-MLF	TNF Receptor	Inflammation/Immunology
N-Formyl-Met-Leu-Phe (fMLP; N-Formyl-MLF) is a chemotactic peptide and a specific ligand of N-formyl peptide receptor (FPR). N-Formyl-Met-Leu-Ph is reported to inhibit *TNF-alpha* secretion.

HY-W014049

N'-Nitro-D-arginine	NO Synthase	Others
N'-Nitro-D-arginine, a nitric oxide synthesis inhibitor, also is a vasodilator that relaxes the smooth muscles and increases blood flow to the penis, improving erections. N'-Nitro-D-arginine also inhibits neutrophil migration by blocking receptors for tumour necrosis factor alpha (TNFα) and interleukin 8 (IL8) .

HY-12557

γ-Glutamylvaline	CaSR Wnt TNF Receptor	Inflammation/Immunology
γ-Glutamylvaline is an activator of CaSR with anti-inflammatory activity. γ-Glutamylvaline inhibits *TNF-α*-induced proinflammatory cytokine production and increases Wnt5a expression. γ-Glutamylvaline activates calcium-sensing receptor pathways in adipocytes of 3T3-L1 mice and prevents low-grade chronic inflammation .

HY-P2612

WP9QY	TNF Receptor	Others
WP9QY, TNF-a Antagonist, TNF-a Antagonist is a biological active peptide. (This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I. It prevents interactions of TNF with its receptor. This TNF antagonist is a useful template for the development of small molecular inhibitors to prevent both inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.)

Cat. No.	Product Name	Target	Research Area

HY-108847

Etanercept 4 Publications Verification	TNF Receptor Bacterial	Inflammation/Immunology Cancer
Etanercept, a dimeric fusion protein that binds TNF, acts as a *TNF* inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .

HY-P99008

Atibuclimab 1 Publications Verification	Inhibitory Antibodies	Inflammation/Immunology
Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis . Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist .

HY-P99361

Enavatuzumab PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)	TNF Receptor	Cancer
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0297

Sinensetin 5 Publications Verification Pedalitin permethyl ether	Structural Classification Flavonoids other families Classification of Application Fields Flavones Source classification Other Diseases Plants Disease Research Fields	PGE synthase TNF Receptor
Sinensetin is a methylated flavonoid found in fruits that has strong anti-vascular and anti-inflammatory properties.

HY-124151

Adenosine-2'-monophosphate 2'-AMP; Adenosine 2'-phosphate; AMP 2'-phosphate	Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Adenosine Receptor Endogenous Metabolite
Adenosine-2'-monophosphate (2'-AMP) is converted by extracellular 2’,3'-CAMP. Adenosine-2'-monophosphate is further metabolized to extracellular adenosine (a mechanism called the extracellular 2’,3’-cAMP-adenosine pathway). Adenosine-2'-monophosphate inhibits LPS-induced TNF-α and CXCL10 production via A_2A receptor activation .

HY-N11768

4-Methoxylonchocarpin	Structural Classification Monophenols Source classification Phenols Plants Moraceae Dorstenia mannii Hook.f.	NF-κB Interleukin Related Toll-like Receptor (TLR)
4-Methoxylonchocarpin is an orally active anti-inflammatory agent. 4-methoxylonchocarpin inhibits the binding of LPS to *Toll-like Receptor* (TLR) TLR4** to inhibit NF-κB activation and TNF Receptor and IL-6 expression. 4-Methoxylonchocarpin also inhibits the phosphorylation of TGF-beta activated kinase 1 and TNBS-induced expression of IL-1β, IL-17A, and TNF. 4-methoxylonchocarpin can improve 2,4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis mouse model .

Cat. No.	Compare	Product Name	Species	Source

HY-P70815

	TNFRSF10C Protein, Human (HEK293, His) Tumor Necrosis Factor Receptor Superfamily Member 10C; Antagonist Decoy Receptor for TRAIL/Apo-2L; Decoy TRAIL Receptor Without Death Domain; Decoy Receptor 1; DcR1; Lymphocyte Inhibitor of TRAIL; TNF-Related Apoptosis-Inducing Ligand Receptor 3; TRAIL Receptor	Human	HEK293
	The TNFRSF10C protein is a receptor for TRAIL and lacks a cytoplasmic death domain, making it unable to induce apoptosis. Instead, it protects cells by competing for ligand binding with TRAIL-R1 and R2, acting as a decoy receptor and mitigating TRAIL-mediated apoptosis. TNFRSF10C Protein, Human (HEK293, His) is the recombinant human-derived TNFRSF10C protein, expressed by HEK293 , with C-6*His labeled tag. The total length of TNFRSF10C Protein, Human (HEK293, His) is 196 a.a., with molecular weight of 50-60 kDa.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-130252

YQ128 1 Publications Verification		Alkynes
YQ128 is a potent and selective second-generation *NLRP3 (NOD-like receptor* P3) inflammasome** inhibitor with an IC₅₀ of 0.30 μM. YQ128 significantly and selectively suppresses the production of IL-1β, but not TNF-α, and it can cross the BBB to reach the CNS. YQ128 has anti-inflammatory activity . YQ128 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Click Chemistry